Bioequivalence of lisdexamfetamine dimesylate hard capsules formulations
DOI:
https://doi.org/10.24933/rep.v8i1.443Keywords:
Attention deficit disorder; hyperactive; lisdexamfetamine dimesylate; bioequivalence; biological availability; pharmacokinetics.Abstract
Lisdexamfetamine (LDX), an inactive prodrug of dexamphetamine, is used as a second-line treatment for attention deficit hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder (BED). The objective of this study is to evaluate the bioequivalence of two LDX formulations, including the reference product manufactured by Patheon Pharmaceuticals (Venvanse® 70 mg) versus a formulation manufactured by Eurofarma Laboratórios S/A. A randomized, crossover, open-label study was conducted with two treatments, two periods, two sequences, and 48 healthy participants of both sexes who received oral administration of the medications. A total of 24 blood samples were collected from each participant, from T0 (before taking the medication) to 10 hours later. The plasma concentration of LDX was quantified using liquid chromatography coupled with mass spectrometry (LC-MS/MS). Both formulations were well tolerated, and no serious adverse events were reported. Cmax and AUC0-t were compared: the ratio between the test and reference formulations for Cmax was 106.22% with a 95% confidence interval (CI) of 97.72% - 116.66% and a power of 98.75%. The ratio between the test and reference formulations for AUC0-t was 106.28%, CI (100.68% - 112.19%), with a power of 100.00%. The ratio between the test and reference formulations for AUC0-inf was 106.29%, CI (100.71% - 112.17%), with a power of 100.00%. The formulations were shown to be statistically bioequivalent in terms of their rate and extent of absorption, based on criteria established by the Brazilian Health Regulatory Agency (ANVISA).
Downloads
References
CASTELLS, X.; BLANCO-SILVENTE, L.; CUNILL, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, v. 8, n. 8, CD007813, 9 ago. 2018. DOI: 10.1002/14651858.CD007813.pub3. Disponível em: https://doi.org/10.1002/14651858.CD007813.pub3. DOI: https://doi.org/10.1002/14651858.CD007813.pub3
KRISHNAN, S. M.; PENNICK, M.; STARK, J. G. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clinical Drug Investigation, v. 28, p. 745–755, 2008. DOI: 10.2165/0044011-200828120-00002. DOI: https://doi.org/10.2165/0044011-200828120-00002
HUTSON, P. H.; PENNICK, M.; SECKER, R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel D-amphetamine pro-drug. Neuropharmacology, v. 87, p. 41–50, 2014. DOI: 10.1016/j.neuropharm.2014.02.014. DOI: https://doi.org/10.1016/j.neuropharm.2014.02.014
PENNICK, M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to D-amphetamine. Neuropsychiatric Disease and Treatment, v. 6, p. 317–327, 2010. DOI: 10.2147/ndt.s9749. DOI: https://doi.org/10.2147/NDT.S9749
CERTARA USA, Inc. Phoenix/WinNonlin™: version 8.2 [programa de computador]. Princeton, NJ: Certara, 2019.
SCHUIRMANN, Donald J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, v. 15, n. 6, p. 657-680, 1987. DOI: https://doi.org/10.1007/BF01068419
BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução RE nº 1.170, de 19 de abril de 2006. Diário Oficial da União, Brasília, DF, 21 abr. 2006. Seção 1, p. 43.
MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES (MedDRA), versão 26.1. Londres: ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2023.
BRAZIL. Law No. 9,787, of February 10, 1999. Amends Law No. 6,360, of September 23, 1976, which provides for health surveillance, establishes generic medicine, provides for the use of generic names in pharmaceutical products, and provides other provisions. Official Gazette of the Union, Brasília, DF, February 11, 1999.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anne Michelli Reis Silveira, Simone Grigoleto Schramm, Camila Kaori Aihara, Vitor Enguel Enguel, Renata Gebara de Grande di Sessa di Sessa, Andréia de Melo Porcari, Marcia Aparecida Antonio
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
a) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
b) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
c) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).
